

Security Officer, HS-1/Forrestal Building”.

■ c. Paragraphs (d) and (e) by removing “DOE Director of Security Affairs” and adding in their place “Chief Health, Safety and Security Officer”.

■ d. Paragraph (f) by removing “DOE Director of Security Affairs” and adding in its place “Chief Health, Safety and Security Officer’s”.

#### **PART 1046—PHYSICAL PROTECTION OF SECURITY INTERESTS**

■ 145. The authority citation for part 1046 continues to read as follows:

**Authority:** Sec. 2201, Pub. L. 83-703, 68 Stat. 919 (42 U.S.C. 2201 *et seq.*); sec. 7151, Pub. L. 95-91, 91 Stat. 565 (42 U.S.C. 7101 *et seq.*).

##### **§ 1046.3 [Amended]**

■ 146. Section 1046.3 is amended in the definition of “Designated physician” by removing “Medical Director, Office of Operational and Environmental Safety, Headquarters” and adding in its place “Director, Office of Health and Safety” and by removing “Medical” in the second sentence.

#### **Appendix A to Subpart B of Part 1046 [Amended]**

■ 147. Appendix A is amended in:

■ a. Section B.(9) by removing “Director of Safeguards and Security, Headquarters,” and adding in its place “Chief Health, Safety and Security Officer”.

■ b. Section G.(1)(e) by removing “Director of Safeguards and Security, DOE Headquarters,” and adding in its place “Chief Health, Safety and Security Officer”.

■ c. Section J.(5) by removing “Director of Safeguards and Security, DOE Headquarters” and adding in its place “Chief Health, Safety and Security Officer”.

#### **Appendix B to Subpart B of Part 1046 [Amended]**

■ 148. Appendix B is amended in:

■ a. Section B.(1) by removing “Central Training Academy (CTA)” and adding in its place “National Training Center,” and by removing “Director, Office of Safeguards and Security” and adding in its place “Chief Health, Safety and Security Officer”.

■ b. Section B.(9)(b) is amended by removing “DOE Operations Office” and adding in its place “DOE field office”.

■ c. Section B.(9)(g) by removing “Office of Safeguards and Security (SA-10)” and adding in its place “Chief Health, Safety and Security Officer”.

■ d. Section B.(9)(i) by removing “Central Training Academy” and

adding in its place “National Training Center”.

#### **PART 1049—LIMITED ARREST AUTHORITY AND USE OF FORCE BY PROTECTIVE FORCE OFFICERS OF THE STRATEGIC PETROLEUM RESERVE**

■ 149. The authority citation for part 1049 continues to read as follows:

**Authority:** 42 U.S.C. 7101 *et seq.*

##### **§ 1049.8 [Amended]**

■ 150. Section 1049.8(a) is amended by removing “Department of Energy Office of Safeguards and Security” and adding in its place “Chief Health, Safety and Security Officer”.

[FR Doc. E6-20104 Filed 11-27-06; 8:45 am]

**BILLING CODE 6450-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Food and Drug Administration**

#### **21 CFR Part 520**

#### **Oral Dosage Form New Animal Drugs; Neomycin**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Sparhawk Laboratories, Inc. The ANADA provides for use of neomycin sulfate oral solution in livestock for the treatment and control of bacterial enteritis.

**DATES:** This rule is effective November 28, 2006.

**FOR FURTHER INFORMATION CONTACT:** John K. Harshman, Center for Veterinary Medicine (HFV-104), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0169, e-mail: [john.harshman@fda.hhs.gov](mailto:john.harshman@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215, filed ANADA 200-379 for the use of Neomycin Liquid in cattle, swine, sheep, and goats for the treatment and control of bacterial enteritis. Sparhawk Laboratories, Inc.’s Neomycin Liquid is approved as a generic copy of Pharmacia & Upjohn Co.’s BIOSOL Liquid, sponsored by Pharmacia & Upjohn Co., a Division of Pfizer, Inc., under ANADA 200-113. The ANADA is approved as of October

24, 2006, and the regulations in 21 CFR 520.1484 are amended to reflect the approval. The basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

FDA has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

#### **List of Subjects in 21 CFR Part 520**

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

#### **PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS**

■ 1. The authority citation for 21 CFR part 520 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

##### **§ 520.1484 [Amended]**

■ 2. In paragraph (b)(3) of § 520.1484, add “058005,” in numerical sequence.

Dated: November 16, 2006.

**Bernadette Dunham,**

*Deputy Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.*

[FR Doc. E6-20126 Filed 11-27-06; 8:45 am]

**BILLING CODE 4160-01-S**